- Evaluate the epidemiological and economic impact of chronic pain in the United States, including the three distinct waves of the opioid epidemic and the disproportionate burden on rural populations and historically marginalized communities.
- Distinguish among nociceptive, neuropathic, and nociplastic pain mechanisms and apply the 2020 IASP definition of pain to support a holistic, biopsychosocial approach to pain management.
- Identify systemic racial and ethnic inequities in pain assessment and management and discuss evidence-based strategies to advance health equity across clinical practice settings.
- Analyze the CRNA's distinctive clinical role in mitigating the dual crises of chronic pain and opioid misuse.
- Identify the key philosophical and structural differences between the 2016 and 2022 CDC Clinical Practice Guidelines for Prescribing Opioids for Pain, including the shift from rigid prescribing thresholds toward individualized, patient-centered risk-benefit analysis and shared decision-making.
- Describe the evidence-based methodology underlying the 2022 CDC Guideline, including the role of the five AHRQ-commissioned systematic reviews and the GRADE framework in evaluating and weighting evidence across opioid, non-opioid pharmacologic, and non-pharmacologic treatment modalities.
- Apply the 12 recommendations from the 2022 CDC Guideline to CRNA practice in perioperative and chronic pain clinic settings.
- Compare the analgesic efficacy of non-opioid pharmacologic and nonpharmacologic therapies to opioids for acute, subacute, and chronic pain across clinically relevant conditions, as outlined in CDC 2022 Clinical Practice Guideline Recommendations 1 and 2.
- Select appropriate first-line nonpharmacologic and non-opioid pharmacologic interventions for specific acute and chronic pain conditions, applying knowledge of mechanism of action, dosing, side effects, drug interactions, and contraindications to individualized patient care.
- Evaluate the risks associated with opioid therapy for acute, subacute, and chronic pain, and articulate the clinical rationale for prioritizing non-opioid multimodal pain management strategies.
- Identify opportunities for CRNAs with advanced pain management training to expand access to evidence-based interventional and multimodal pain care, particularly in underserved and rural communities.
- Differentiate between the risks of immediate-release and extended-release/long-acting opioid formulations when initiating therapy for acute, subacute, or chronic pain.
- Apply morphine milligram equivalent (MME) conversions to calculate safe initiation doses for opioid-naive patients, recognizing the dose-dependent relationship between opioid exposure and risk of overdose, persistent use, and other serious adverse effects.
- Implement the principles of CDC Recommendations 3 and 4 in clinical practice by prescribing the lowest effective opioid dose for the shortest necessary duration, establishing a clear reassessment and discontinuation plan at initiation, and accounting for patient-specific factors, including renal and hepatic function, comorbidities, and concomitant CNS-depressant medications.
- Apply CDC Recommendation 6 in clinical practice by determining the appropriate opioid prescription duration and quantity based on the nature and severity of tissue injury.
- Identify the clinical circumstances that warrant reassessment of ongoing opioid therapy, including indications for dose reduction or discontinuation, using the HHS Guide for Clinicians framework and CDC Recommendation 5 to guide individualized, collaborative tapering decisions.
- Develop a safe, patient-centered opioid tapering plan that accounts for duration of prior opioid use, rate of dose reduction, withdrawal symptom management, naloxone counseling, and integration of non-opioid therapies, recognizing the serious harms associated with abrupt discontinuation or rapid dose reduction.
- Implement the follow-up schedule outlined in CDC Recommendation 7 by establishing appropriate reassessment intervals based on opioid formulation, dose, and patient risk factors, and apply systematic monitoring criteria to guide decisions about continuation, dose adjustment, or discontinuation of opioid therapy.
- Evaluate patient-specific risk factors for opioid-related harm, including comorbidities such as sleep apnea, renal/hepatic disease, psychiatric conditions, and concurrent CNS depressant use, and apply CDC Guideline Recommendation 8 to construct an individualized, collaborative risk-mitigation plan that incorporates naloxone prescribing where indicated.
- Critically appraise the role of Prescription Drug Monitoring Programs (PDMP) and toxicology screening in safe opioid prescribing by interpreting results from these screenings within the broader clinical context, while recognizing the potential for bias and need to avoid punitive application of these tools.
- Apply evidence-based strategies to manage high-risk prescribing scenarios, including concurrent opioid and benzodiazepine therapy, post-overdose care, and pain management in vulnerable populations such as pregnant patients, older adults, and those with opioid use disorder, in accordance with CDC Clinical Practice Guideline Recommendations 9–11.
- Recognize opioid use disorder using DSM-5 criteria and apply a non-stigmatizing, patient-centered framework to initiate or coordinate evidence-based treatment with medications for opioid use disorder (MOUD) including buprenorphine, methadone, and naltrexone.
- Compare the pharmacologic mechanisms, clinical indications, and perioperative implications of buprenorphine, methadone, and naltrexone, including their receptor interactions with intraoperative opioids, and apply ASAM National Practice Guideline principles to construct an individualized perioperative management plan.
- Describe the legal and regulatory requirements for prescribing MOUD, including current rules governing buprenorphine and methadone, and identify referral resources and care coordination strategies that support OUD treatment.
- Review the scope and limitations of the 2022 CDC Clinical Practice Guideline as applied to CRNA practice.
- Apply multimodal, opioid-sparing analgesia principles to the perioperative care plan to minimize postoperative opioid requirements at discharge.
- Construct an individualized patient counseling plan for initiating outpatient opioid therapy that incorporates shared decision-making, realistic functional goal-setting, risk disclosure, safe storage and disposal guidance, and naloxone prescribing in accordance with CDC Clinical Practice Guideline recommendations.
|